{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:51:51Z","timestamp":1792266711382,"version":"4.4.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with distinct pathologic and clinical characteristics. Unlike the malignant cells in classical Hodgkin lymphoma, the disease-defining lymphocyte-predominant cells in NLPHL are consistently positive for CD20, but do not express CD30. The clinical course of NLPHL is indolent in the majority of cases. Most patients present with early-stage disease at the initial diagnosis. First-line treatment of stage IA NLPHL usually consists of limited-field radiotherapy alone. Patients with early-stage NLPHL other than stage IA and intermediate-stage disease mostly receive combined-modality treatment, whereas individuals with advanced NLPHL are treated with chemotherapy alone. In relapsed NLPHL, conventional chemotherapy, anti-CD20 antibodies, and radiotherapy represent active treatment modalities. Only patients with poor-risk characteristics such as early disease recurrence are candidates for aggressive salvage treatment with high-dose chemotherapy and autologous stem cell transplantation. The overall and relative survival of patients with NLPHL is excellent as indicated by a low excess mortality compared with the general population. This article discusses treatment options for patients with NLPHL and factors that influence the choice of therapy on the basis of the available data and 2 clinical cases.<\/jats:p>","DOI":"10.1182\/blood.2019004044","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T19:44:18Z","timestamp":1599075858000},"page":"2987-2993","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":57,"title":["How I treat nodular lymphocyte-predominant Hodgkin lymphoma"],"prefix":"10.1182","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1927-3514","authenticated-orcid":false,"given":"Dennis A.","family":"Eichenauer","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Cologne, Germany; and"},{"name":"German Hodgkin Study Group (GHSG), First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Cologne, Germany; and"},{"name":"German Hodgkin Study Group (GHSG), First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020122416305816200_B1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/asheducation-2017.1.324","article-title":"Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management","volume":"2017","author":"Eichenauer","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"2020122416305816200_B2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin\u2019s lymphoma: a comprehensive analysis from the German Hodgkin Study Group","volume":"26","author":"Nogov\u00e1","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020122416305816200_B3","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3324\/haematol.2015.133025","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study","volume":"100","author":"Lazarovici","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2020122416305816200_B4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pathol.2019.10.003","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell\/histiocyte rich large B-cell lymphoma","volume":"52","author":"Hartmann","year":"2020","journal-title":"Pathology"},{"issue":"10","key":"2020122416305816200_B5","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/00000478-200310000-00007","article-title":"Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation","volume":"27","author":"Fan","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"26","key":"2020122416305816200_B6","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood-2013-07-515825","article-title":"The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"122","author":"Hartmann","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2020122416305816200_B7","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/ajh.25607","article-title":"The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma","volume":"94","author":"Hartmann","year":"2019","journal-title":"Am J Hematol"},{"issue":"7","key":"2020122416305816200_B8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1200\/JCO.19.00986","article-title":"Long-term follow-up of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the HD7 to HD15 trials: a report from the German Hodgkin Study Group","volume":"38","author":"Eichenauer","year":"2020","journal-title":"J Clin Oncol"},{"issue":"14","key":"2020122416305816200_B9","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood-2018-02-836437","article-title":"Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group","volume":"132","author":"Eichenauer","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2020122416305816200_B10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin\u2019s lymphoma","volume":"28","author":"Al-Mansour","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020122416305816200_B11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjh.16290","article-title":"Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993-2016","volume":"189","author":"Posthuma","year":"2020","journal-title":"Br J Haematol"},{"issue":"26","key":"2020122416305816200_B12","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.2014.60.4363","article-title":"Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"33","author":"Eichenauer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"16","key":"2020122416305816200_B13","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2020122416305816200_B14","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/leu.2015.321","article-title":"Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group","volume":"30","author":"Eichenauer","year":"2016","journal-title":"Leukemia"},{"issue":"9976","key":"2020122416305816200_B15","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"2020122416305816200_B16","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/annonc\/mdi323","article-title":"Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin\u2019s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)","volume":"16","author":"Nogov\u00e1","year":"2005","journal-title":"Ann Oncol"},{"issue":"1","key":"2020122416305816200_B17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin\u2019s lymphoma: patient outcomes from a large, single-institution series with long follow-up","volume":"28","author":"Chen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020122416305816200_B18","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2018029140","article-title":"Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma","volume":"3","author":"Pinnix","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"2020122416305816200_B19","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/s41375-019-0609-3","article-title":"Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group","volume":"34","author":"Eichenauer","year":"2020","journal-title":"Leukemia"},{"issue":"20","key":"2020122416305816200_B20","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.2015.65.3469","article-title":"Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma: a report from the Children\u2019s Oncology Group","volume":"34","author":"Appel","year":"2016","journal-title":"J Clin Oncol"},{"issue":"17","key":"2020122416305816200_B21","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","article-title":"Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome","volume":"118","author":"Savage","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2020122416305816200_B22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bjh.13879","article-title":"Rituximab-ABV(D) for patients with nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy","volume":"175","author":"Garciaz","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2020122416305816200_B23","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bjh.14001","article-title":"Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma","volume":"176","author":"Cencini","year":"2017","journal-title":"Br J Haematol"},{"issue":"6","key":"2020122416305816200_B24","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1111\/bjh.16109","article-title":"Frontline management of nodular lymphocyte predominant Hodgkin lymphoma\u2014a retrospective UK multicentre study","volume":"186","author":"Wilson","year":"2019","journal-title":"Br J Haematol"},{"issue":"9","key":"2020122416305816200_B25","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1080\/0284186X.2018.1450522","article-title":"R-bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma","volume":"57","author":"Prusila","year":"2018","journal-title":"Acta Oncol"},{"issue":"4","key":"2020122416305816200_B26","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.ijrobp.2008.09.049","article-title":"Low-dose involved-field radiotherapy as alternative treatment of nodular lymphocyte predominance Hodgkin\u2019s lymphoma","volume":"74","author":"Haas","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"26","key":"2020122416305816200_B27","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1182\/blood.2019003877","article-title":"Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG","volume":"135","author":"Binkley","year":"2020","journal-title":"Blood"},{"key":"2020122416305816200_B28","author":"Eichenauer","year":"2020"},{"issue":"24","key":"2020122416305816200_B29","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease [published correction appears in N Engl J Med. 2005;353(7):744]","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"2020122416305816200_B30","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2013-07-512657","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"123","author":"Eichenauer","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2020122416305816200_B31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials","volume":"31","author":"Behringer","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020122416305816200_B32","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3324\/haematol.2017.167478","article-title":"Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials","volume":"102","author":"Eichenauer","year":"2017","journal-title":"Haematologica"},{"issue":"23","key":"2020122416305816200_B33","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1182\/blood-2013-12-541078","article-title":"Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis","volume":"123","author":"Xing","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020122416305816200_B34","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood-2017-02-766121","article-title":"Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma","volume":"130","author":"Fanale","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2020122416305816200_B35","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","article-title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"32","author":"Advani","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10114","key":"2020122416305816200_B36","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"2020122416305816200_B37","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1200\/JCO.2009.26.3293","article-title":"What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin\u2019s lymphoma?","volume":"28","author":"Canellos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"20","key":"2020122416305816200_B38","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood-2018-10-877761","article-title":"Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"133","author":"Borchmann","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2020122416305816200_B39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","article-title":"Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)","volume":"111","author":"Schulz","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2020122416305816200_B40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajh.24927","article-title":"High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: a retrospective study by the European Society for Blood and Marrow Transplantation-Lymphoma Working Party","volume":"93","author":"Akhtar","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"2020122416305816200_B41","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.bbmt.2013.03.008","article-title":"High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"19","author":"Karuturi","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020122416305816200_B42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24819","article-title":"Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group","volume":"116","author":"Biasoli","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"2020122416305816200_B43","doi-asserted-by":"crossref","first-page":"589","DOI":"10.6004\/jnccn.2012.0061","article-title":"Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines","volume":"10","author":"Hoppe","year":"2012","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/26\/2987\/1795444\/bloodbld2019004044c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/26\/2987\/1795444\/bloodbld2019004044c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T16:51:21Z","timestamp":1608828681000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/136\/26\/2987\/463607\/How-I-treat-nodular-lymphocyte-predominant-Hodgkin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,24]]},"references-count":43,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2020,12,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019004044","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,24]]}}}